P547: Characteristics and Outcomes of Patients With Acute Myeloid Leukaemia Treated With Venetoclax Combination Therapy: Real-World Experience in Both Frontline and Relapsed/Refractory Settings

Abstract

Background: Background:Venetoclax (Ven) in combination with hypomethylating agents, such as azacitidine (Aza) and low dose cytarabine (LDAC) has been shown to be effective therapy in acute myeloid leukaemia (AML) and has become standard of care for newly-diagnosed patients unfit for intensive chemotherapy (